HOME >> BIOLOGY >> NEWS
Three nations agree to share ice core thatmay yield clues about nature of Lake Vostok

Scientists from the United States, France and Russia will equally share samples of an 11.7-meter (38.5-foot) ice core taken from the ice sheet above Lake Vostok, deep in the Antarctic interior, under the terms of an agreement worked out among representatives of the nations Antarctic research programs.

Glaciologists, geochemists and biologists will use the lower portions of the Vostok ice core, which was drilled in 1998, to learn more about the subglacial lake known to exist under the ice at Russias Vostok Station, high on the polar plateau. Joint investigative protocols will allow scientists to explore some intriguing questions about the lake while insuring the compatibility and consistency of individual investigations.

Major questions that will provide the framework for future research on the ice core include: How is the ice formed and what is its age? What does the geochemistry of the ice reveal about the lake and its origin? What kinds of organisms are present in the lake and how did they get there?

The agreement was reached at a meeting of U.S., French and Russian scientists held in April at the National Science Foundation (NSF) headquarters in Arlington, Va. Participants included the directors of the U.S., French and Russian Antarctic programs as well as scientists and program managers who support or conduct research on the Vostok ice core.

NSF funds and manages the U.S. Antarctic Program, which supports almost all U.S. research on the continent and in surrounding waters.

The ice samples were drilled at Vostok Station under the terms of a U.S., French and Russian scientific collaboration that has made important contributions to the understanding the last 420,000 years of the Earth's climate. Research on these samples has delivered valuable insights for understanding the forces that drive climate change.

The samples governed by the agreement were left at Vostok Station until the 2001-2002 austral summer, whe
'"/>

Contact: Peter West
pwest@nsf.gov
703-292-8070
National Science Foundation
28-May-2002


Page: 1 2

Related biology news :

1. Three new South American fish identified
2. Three personal ads for physics
3. Three molecular-targeted compounds show promise against cancers
4. Three genes linked to psoriasis susceptibility identified on chromosome 17
5. Three Pacific Northwest National Laboratory inventions win R&D 100 Awards
6. Three Gorges Dam is an opportunity for ecoscience
7. Three tourist experiences named best worldwide for environmental, social responsibility
8. Three inferior prefrontal regions of the brain found receptive to somatosensory stimuli
9. Three dimensional structure of a protein transport machine
10. Three studies released this week shed new light on eating nuts for good health
11. Three-D images shed light on first steps of RNA synthesis

Post Your Comments:
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: